Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects With Metastatic Malignant Melanoma

Sponsor
Celgene Corporation (Industry)
Overall Status
Completed
CT.gov ID
NCT00055562
Collaborator
(none)
274
31
23
8.8
0.4

Study Details

Study Description

Brief Summary

Subjects are randomized to one of two treatment arms. All subjects are screened for eligibility within 28 days prior to randomization. The study consists of a treatment phase and a follow-up phase. Subjects will be treated in repeating 4 week cycles.

Condition or Disease Intervention/Treatment Phase
  • Drug: CC 5013
Phase 2/Phase 3

Study Design

Study Type:
Interventional
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double
Primary Purpose:
Treatment
Official Title:
Multicenter, Randomized, Controlled, Double-Blind, Parallel-Group Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects With Metastatic Malignant Melanoma Whose Disease Has Progressed on Treatment With DTIC, IL-2 or IFN Based Therapy
Study Start Date :
Jan 1, 2003
Study Completion Date :
Dec 1, 2004

Outcome Measures

Primary Outcome Measures

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    • Understand and voluntarily sign an informed consent form.

    • Able to adhere to the study visit schedule and other protocol requirements.

    • Metastatic malignant melanoma now stage IV, relapsed or refractory to standard metastatic therapy.

    • Women of childbearing potential must have a negative serum or urine pregnancy test within 7 days of starting study drug.

    • Patients with active brain disease, or newly diagnosed brain metastases, within 4 weeks prior to the start of study treatment are excluded.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 University of Arizona Cancer Center Tucson Arizona United States 85724
    2 University of Southern California Norris Cancer Center Los Angeles California United States 90089
    3 UCLA Los Angeles California United States 90095-6956
    4 St. Francis Memorial Hospital San Francisco California United States 94109
    5 Outpatient Clinic Santa Monica California United States 90404
    6 University of Colorado Aurora Colorado United States 80010
    7 The Harold Lever Regional Cancer Center Waterbury Connecticut United States 06708
    8 Lakeland Regional Cancer Center Lakeland Florida United States 33804-1057
    9 Mount Sinai Comprehensive Cancer Center Miami Beach Florida United States 33140
    10 Lutheran General Park Ridge Illinois United States 60068-1270
    11 Carle Clinic Urbana Illinois United States 61801
    12 Massachusetts General Hospital Boston Massachusetts United States 02214-2698
    13 Beth Israel Deaconess Medical Ctr Boston Massachusetts United States 02215-5400
    14 Spectrum Health Grand Rapids Michigan United States 49503
    15 Ellis Fischel Cancer Center Columbia Missouri United States 65203
    16 Washington University School of Medicine St. Louis Missouri United States 63110
    17 Melanoma Center of St Louis St. Louis Missouri United States 63131
    18 Biomedical Research Alliance of New York New York New York United States 10016
    19 Memorial Sloan Kettering Cancer Center New York New York United States 10021
    20 The Linder Clinical Trial Center Cincinnati Ohio United States 45219
    21 Cleveland Clinic Foundation Cleveland Ohio United States 44195
    22 Penn State Hershey Medical Center Hershey Pennsylvania United States 17033-0850
    23 UPMC Cancer Pavillion Pittsburgh Pennsylvania United States 15232
    24 Sarah Cannon Cancer Center Nashville Tennessee United States 37203-1632
    25 MD Anderson Cancer Center Houston Texas United States 77030-4009
    26 Tom Baker Cancer Center Calgary Alberta Canada T2N 4N2
    27 Cross Cancer Institute Edmonton Alberta Canada T6G 1Z2
    28 Cancer Care Manitoba Winnipeg Manitoba Canada R3E 0V9
    29 Qell Health Sciences Center Halifax Nova Scotia Canada B3H 2y9
    30 Princess Margaret Hospital Toronto Ontario Canada M5G 2M9
    31 L'Hotel Dieu de Quebec Quebec Canada PQ G1R 2J6

    Sponsors and Collaborators

    • Celgene Corporation

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    , ,
    ClinicalTrials.gov Identifier:
    NCT00055562
    Other Study ID Numbers:
    • CDC-5013-MEL-001
    • NCT00060281
    First Posted:
    Mar 6, 2003
    Last Update Posted:
    Jun 24, 2005
    Last Verified:
    May 1, 2004

    Study Results

    No Results Posted as of Jun 24, 2005